Figure 4.

XH30 inhibits glioblastoma migration. (A) The IC₅₀ value of XH30 in U87MG cells at 24 h. Data are presented as mean ± SD, n = 3. (B) Transwell migration assay in U87MG. The cells were exposed to various concentrations of XH30 (5, 50 and 500 nmol/L) for 24 h. 1% crystal violet staining, scale bar: 250 μm. (C) The count of migrated cells. Data are presented as mean ± SD, n = 3. ANOVA analysis, ∗P < 0.05, ∗∗P < 0.01, compared to control. (D) XH30 downregulated MMP2 expression. U87MG cells were exposed to XH30 for 24 h, then harvested for immunoblotting. (E) IL-17A increased the migration of U87MG cells. The cells were exposed to indicated concentrations of IL-17A for 24 h. 1% crystal violet staining, scale bar: 250 μm. (F) XH30 blocked the activation of PI3K/AKT pathway by IL-17. U87MG cells were incubated with XH30 at indicated concentrations (5, 50 and 500 nmol/L) in the presence or absence of 100 ng/mL hIL-17A for 24 h.